Statements (66)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:associated_with |
MEN 2 syndrome
thyroid nodules C-cell hyperplasia |
| gptkbp:can_metastasize_to |
liver
lungs lymph nodes |
| gptkbp:caused_by |
calcitonin secretion
|
| gptkbp:clinical_trial |
ongoing research
|
| gptkbp:events |
imaging studies
serum calcitonin monitoring |
| gptkbp:first_described_by |
1970s
|
| gptkbp:gender |
more common in women
|
| gptkbp:genetic_diversity |
multiple endocrine neoplasia type 2
RET proto-oncogene |
| https://www.w3.org/2000/01/rdf-schema#label |
medullary thyroid carcinoma
|
| gptkbp:is_popular_in |
rare
|
| gptkbp:is_tested_for |
calcitonin
carcinoembryonic antigen (CEA) |
| gptkbp:location |
thyroid gland
|
| gptkbp:occurs_in |
0.5% of all thyroid cancers
|
| gptkbp:risk_factor |
age
radiation exposure family history genetic mutations gender |
| gptkbp:social_responsibility |
imaging techniques
fine needle aspiration biopsy serum calcitonin levels endocrine evaluation variable based on stage |
| gptkbp:specialties |
lymph node dissection
thyroidectomy |
| gptkbp:symptoms |
fatigue
nausea weight loss abdominal pain vomiting diarrhea difficulty swallowing hoarseness flushing neck mass |
| gptkbp:tour |
gptkb:TNM_system
|
| gptkbp:treatment |
gptkb:hospital
gptkb:vaccine palliative care rehabilitation services clinical trials nutritional support supportive care radiation therapy chemotherapy psychosocial support targeted therapy pain management biological therapy radiopharmaceuticals clinical management hormonal therapy systemic therapy endocrine therapy local therapy |
| gptkbp:type |
gptkb:healthcare_organization
|
| gptkbp:bfsParent |
gptkb:Tirzepatide
|
| gptkbp:bfsLayer |
4
|